Expert Interview
A look UX143 (Setrusumab), an Anti-sclerostin Monoclonal Antibody as a potential therapy for osteogenesis imperfecta
Ticker(s): RAREInstitution: University Hospital Cologne
- Pediatric endocrinologist with a focus on osteology at University Hospital Cologne
- Manages 60 patients per year with osteogenesis imperfecta.
- Has been researching treatment approaches for children with osteogenesis imperfecta since 2015.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
